Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPRESS: Gefitinib + Chemo in EGFR+ NSCLC
NCT01544179Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2012
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Mar 2012; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01544179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01544179.